Endothelial dysfunction and vascular leak, pathogenic hallmarks of severe dengue disease, are directly triggered by dengue virus (DENV) nonstructural protein 1 (NS1). Previous studies have shown that immunization with NS1, as well as passive transfer of NS1-immune serum or anti-NS1 mAb, prevent NS1-mediated lethality in vivo. In this study, we evaluated the immunogenicity and protective capacity of recombinant DENV NS1 administered with cyclic dinucleotides (CDNs), potent activators of innate immune pathways and highly immunogenic adjuvants. Using both wild-type C57BL/6 mice and IFN-a/b receptor-deficient mice, we show that NS1-CDN immunizations elicit serotype-specific and cross-reactive Ab and T cell responses. Furthermore, NS1-CDN vaccinations conferred significant homotypic and heterotypic protection from DENV2-induced morbidity and mortality. In addition, we demonstrate that high anti-NS1 Ab titers are associated with protection, supporting the role of humoral responses against DENV NS1 as correlates of protection. These findings highlight the potential of CDN-based adjuvants for inducing Ab and T cell responses and validate NS1 as an important candidate for dengue vaccine development. The Journal of Immunology, 2019, 202: 000-000.
T he four dengue virus (DENV) serotypes (DENV1-4) are transmitted by Aedes aegypti and A. albopictus mosquitoes, causing up to an estimated 390 million infections and 96 million cases of dengue annually (1) . DENV is an enveloped flavivirus with three structural proteins (capsid, membrane, envelope) and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5). Human DENV infections can range from asymptomatic to dengue fever to the potentially lethal dengue hemorrhagic fever/dengue shock syndrome. During a secondary infection with DENV, Abs to the E protein may trigger Ab-dependent enhancement (ADE), in which they facilitate entry of DENV into Fcg receptor-bearing cells, leading to increased viral load, immune activation, and more severe disease (2) (3) (4) . In contrast, because NS1 is not a structural component of the DENV virion, it is reasoned that Abs to NS1 should not enhance viral uptake.
As an immunogen, formulations based on recombinant NS1 induce strong immune responses and confer protection in rodent models of dengue disease (5) (6) (7) (8) . Furthermore, passive transfer of polyclonal sera from NS1-immunized mice or anti-NS1 mAb into naive mice conferred protection against vascular leak disease, likely by promoting lysis of infected cells and/or by blocking the pathogenic effects of secreted NS1 (5, 9, 10) . Importantly, NS1 is ∼64-79% conserved across the four DENV serotypes (11, 12) , and immunodominant regions of this protein have been identified in both NS1-immunized and DENV-infected mice, as well as in naturally infected humans (10, (13) (14) (15) (16) . The role of NS1-specific CD4 + T cells against DENV infection is a topic of active investigation, and studies have provided evidence of the likely protective effect of these cells (17) (18) (19) (20) . Taken together, these findings support further research of NS1 as an important Ag for dengue vaccine development.
One of the main challenges of nonreplicating vaccines is the use of adjuvants capable of eliciting strong memory T cells and protective Abs (21, 22) . Cyclic dinucleotides (CDNs) are ubiquitous second messengers synthesized by bacteria, which are capable of activating the cytosolic receptor stimulator of IFN genes (STING), resulting in the activation of different immune pathways (23) (24) (25) (26) (27) . Due to their immunostimulatory properties, CDNs were initially used as vaccine adjuvants to elicit protective Ab and T cell responses against pathogenic extracellular bacteria (28-30). However, more recent studies have shown that CDN compounds also have a significant capacity to induce potent antitumor responses (31) (32) (33) and to elicit protective Th1 and Th17 cellular immune responses against Mycobacterium tuberculosis infection (34) .
In this study, we evaluated the immunogenicity of DENV NS1 proteins together with CDN compounds in comparison with monophosphoryl lipid A (MPLA) adjuvant, a TLR4 agonist capable of eliciting strong Th1 responses and high Ab titers (35) (36) (37) (38) that has been approved for human use in vaccines for hepatitis B virus and human papillomavirus infection (39, 40) . Using both wild-type C57BL/6 (WTB6) and IFN-a/b receptor-deficient C57BL/6 (Ifnar 2/2 ) mice, we measured IgG titers and T cell responses after immunizations with each NS1 from all four DENV serotypes. We found that NS1-CDN vaccinations induced balanced Ab responses against all DENV NS1 serotypes, which were comparable or higher in magnitude to those elicited by NS1-MPLA immunizations. Furthermore, NS1-CDN-immunized mice developed serotype-specific and cross-reactive T cell responses, greater than MPLA-adjuvanted NS1, underscoring the ability of CDN compounds to induce cellular immunity. Finally, using a mouse model of lethal DENV infection, we show that NS1 combined with CDNs confers significant protection against DENV-induced morbidity and mortality.
Materials and Methods

Ethics statement
All experimental procedures involving the use of animals were preapproved and performed according to the guidelines of the Institutional Animal Care and Use Committee of the University of California, Berkeley.
Mice
WTB6 and Ifnar 2/2 mice were bred and cohoused in specific pathogen-free conditions at the University of California, Berkeley, Animal Facility. Five-to eight-week-old male and female mice were used for all experimental procedures.
Recombinant NS1 proteins
Recombinant NS1 proteins from DENV serotypes 1 (Nauru/Western Pacific/1974), 2 (Thailand/16681/84), 3 (Sri Lanka D3/H/IMTSSA-SRI/ 2000/1266), and 4 (Dominica/814669/1981) were purchased from The Native Antigen Company (Oxford, U.K.).
Viruses
DENV2 D220 was generated in our laboratory from the parental strain DENV2 PL046 (41) . The virus was propagated in A. albopictus C6/36 cell line (American Type Culture Collection) and titered by plaque assay on baby hamster kidney cells (BHK21, clone 15). The parental strain DENV2 PL046 was obtained originally from H.-Y. Lei (National Cheng Kung University, Taiwan).
NS1 immunizations
Mice were immunized s.c. two times (study days 0 and 21) with 20 mg of NS1 or OVA in combination with 5-15 mg CDN compounds or 1 mg MPLA, each formulated in AddaVax (0.5% sorbitan trioleate, 5% squalene, 0.5% Tween-80 in 10 mM sodium citrate buffer). CDN compounds dithio-(Rp,Rp)-[cyclic [G(29,59) pA (39, 59) p]] (mixed-linkage dithio cGMP-AMP [ML-RR-cGAMP]) and a derivative of this compound consisting of cyclic [G (29, 59) pA (39, 59 )p] comprising Rp,Rp-bisphosphorothiolate linkages (ML-RR-cGAMP-D) were produced by Aduro Biotech as previously reported (31, 34, 42) . MPLA from Salmonella minnesota R595 and AddaVax were acquired from InvivoGen (San Diego, CA).
Anti-NS1 ELISA
Ab responses induced by NS1 were evaluated 1 wk following the second immunization. Blood samples were collected via submandibular bleed to evaluate polyclonal sera against recombinant NS1 by ELISA. Briefly, MaxiSorp ELISA plates (Thermo Scientific Nunc) were coated with 50 ml of NS1 (0.5 mg/ml) and incubated overnight at room temperature. After blocking with 1% BSA in PBS (1% BSA-PBS), wells were incubated for 1 h at room temperature with 100 ml of serial dilutions of polyclonal sera. Plates were then washed and incubated for 1 h at room temperature with peroxidase-labeled goat anti-mouse secondary Abs (Jackson ImmunoResearch) at 0.5 mg/ml in 1% BSA-PBS. After a washing step, the assay was developed using an ABTS-HRP substrate kit (KPL), according to the manufacturer's specifications. Ab titers are reported as area under the curve, calculated using GraphPad Prism 6 software.
T cell assays
T cell responses in mouse spleen were evaluated 1 wk after the second immunization. For ELISpot assays, plate wells were coated with anti-mouse IFN-g Ab (BD Biosciences) and incubated overnight at 4˚C. Plates were then blocked with tissue culture media (RPMI 1640, 10% FCS, and 5% penicillin-streptomycin), and single-cell suspensions (2 3 10 5 cells/well) were incubated with 1 mg/ml NS1 protein, 1 mM OVA CD4 peptide ( 265 TEWTSSNVMEERKIKV 280 ), or 1 mM OVA CD8 peptide ( 257 SIINFEKL 264 ) for a minimum of 18 h at 37˚C. Biotinylated anti-IFN-g Ab (BD Biosciences) was then added, followed by a washing step and addition of streptavidin-conjugated alkaline phosphatase. The assay was developed with nitroblue tetrazolium and 5-bromo-4-chloro-39-indolyphosphate substrate (Thermo Fisher Scientific). For intracellular cytokine staining (ICS), 2 3 10 6 cells were incubated at 37˚C for 1 h with 1 mg/ml DENV NS1 protein, followed by 4 h in the presence of 1 mg/ml brefeldin A (GolgiPlug; BD Biosciences) and 2 mM monensin (GolgiStop; BD Biosciences). Cells were stained with the viability dye Zombie Green (BioLegend), CD8a-BUV395, CD4-BUV737, Ly6G-FITC, CD90.2 V500 (BD Biosciences), and MHCII-FITC (BioLegend). Cells were then treated with Cytofix/Cytoperm Fixation/Permeabilization Kit (BD Biosciences) and stained with IL-2 PE, TNF-a-PE/Cy7, IFN-g APC/ 647 (BioLegend).
In vitro assessment of ADE
Serial dilutions of polyclonal sera were mixed with DENV2 D220 for 1 h at 37˚C and then mixed with human erythroleukemic K562 cells at a multiplicity of infection of 1 for 24 h in a 96-well plate. Cells were then washed with FACS buffer and fixed in 2% paraformaldehyde for 10 min at room temperature. Cells were stained using 2.5 mg/ml 4G2-Alexa 488 (Invitrogen) upon permeabilization with FACS buffer containing 0.1% saponin (Sigma-Aldrich). K562 cells were then washed, and the percentage of infection was determined using Guava flow cytometer (EMD Millipore) by gating Alexa 488-positive cells.
DENV challenge experiments
To evaluate the protective capacity of DENV NS1-CDN vaccinations, immunized Ifnar 2/2 mice were challenged with 5 mg of 4G2 (antienvelope mAb) 20-24 h prior to infection with 3 3 10 5 PFU of DENV2 D220. Virus challenge was administered by i.v. injection 4 wk after the second immunization, and mice were monitored every 12 h using a morbidity scoring system on a scale of 1-5 (41). Mice were immediately euthanized when they became moribund (score of 5).
Statistical analysis
Data were analyzed and plotted using GraphPad Prism 6 software. Differences in Ab and T cell responses between two treatment groups were evaluated using a two-sided unpaired Student t test. Comparison of survival rates was conducted using a log-rank (Mantel-Cox) test and graphed as Kaplan-Meier survival curves. (Fig. 1A, 1D ). ELISpot analysis of T cell responses in spleen showed higher IFN-g production in mice immunized with NS1 in combination with ML-RR-cGAMP or ML-RR-cGAMP-D as compared with MPLA-NS1-vaccinated animals ( Fig. 1B, 1E ). A similar trend was observed by ICS analysis, which also revealed higher TNF-a and IL-2 production as a result of CDN-NS1 immunizations, indicating a polyfunctional T cell activation status (Fig. 1C, 1F ). In addition, immunizations with ML-RR-cGAMP or ML-RR-cGAMP-D in combination with OVA induced significantly higher CD4 + and CD8 + T cell responses in both WTB6 and Ifnar 2/2 mice (Supplemental Fig. 1 ).
Results
CDN compounds induce robust anti-NS1 Ab and T cell responses
ML-RR-cGAMP-D elicits balanced anti-NS1 humoral responses against all DENV NS1 serotypes and induces a Th1-associated Ab profile in WTB6 mice
To evaluate the effect of CDNs on the induction of serotype-specific and cross-reactive DENV NS1 Ab responses, mice were immunized with NS1 from DENV serotypes 1-4 in combination with ML-RR-cGAMP-D or MPLA. Ab responses in polyclonal sera were measured by ELISA using recombinant NS1 from all four DENV serotypes. In general, immunization with DENV NS1 in combination with ML-RR-cGAMP-D or MPLA resulted in comparable anti-NS1 responses in both WTB6 and Ifnar 2/2 mice.
However, WTB6 mice immunized with DENV3 NS1 in combination with ML-RR-cGAMP-D developed higher anti-DENV1 NS1 and anti-DENV3 NS1 IgG titers than when MPLA was used as an adjuvant. Similarly, DENV2 NS1-ML-RR-cGAMP-D-immunized WTB6 animals generated higher anti-DENV2 NS1 titers than DENV2 NS1-MPLA-immunized mice ( Fig. 2A, 2B ). In contrast, MPLA-adjuvanted DENV2 NS1 and DENV3 NS1 induced stronger IgG2b responses than those elicited by ML-RR-cGAMP-D-adjuvanted vaccinations in Ifnar 2/2 mice, although no significant differences were found in WTB6 animals (Supplemental Fig. 2B, 2E ). Finally, IgG3 titers elicited by ML-RR-cGAMP-D or MPLA in combination with NS1 were comparable among all DENV NS1 serotypes, in both WTB6 and Ifnar 2/2 mice (Supplemental Fig. 2C, 2F ).
ML-RR-cGAMP-D induces serotype-specific and cross-reactive DENV NS1 T cell responses
Several studies have established that CDN compounds are effective inducers of T cell immune responses (reviewed in Ref. 27 ). To assess the ability of ML-RR-cGAMP-D to elicit cellular immunity against the different DENV serotype NS1 proteins, we measured responses in the spleen of immunized mice using ELISpot assays. In WTB6 mice, immunization with DENV2 NS1 or DENV3 NS1 in combination with ML-RR-cGAMP-D elicited significantly higher IFN-g serotype-specific production than MPLA-NS1 vaccination (Fig. 3A) . A similar trend was observed in Ifnar 2/2 mice, where DENV2 NS1 and DENV4 NS1 adjuvanted with ML-RR-cGAMP-D induced significantly stronger responses than MPLA-adjuvanted The Journal of Immunologyimmunization (Fig. 3C ). Cross-reactive responses were assessed by stimulating splenocytes with each of the NS1 proteins from the DENV serotypes that were not used for immunization (e.g., splenocytes from mice immunized with DENV1 NS1 were stimulated with NS1 proteins from DENV serotypes 2, 3, and 4). Notably, in both WTB6 and Ifnar 2/2 mice, immunization with DENV3 NS1 in combination with ML-RR-cGAMP-D resulted in strong IFN-g responses against DENV1 NS1. However, immunization with NS1 from DENV serotypes 1, 2, and 4 failed to induce considerable cross-reactive responses, and none of the MPLAadjuvanted immunizations elicited significant IFN-g production (Fig. 3B, 3D) . Finally, ICS analysis of cross-reactive CD4 + T cell responses from immunized WTB6 mice showed similar results to those from ELISpot assays. Vaccination with DENV2 NS1 or DENV3 NS1 adjuvanted with ML-RR-cGAMP-D elicited significant serotype-specific IFN-g, TNF-a, and IL-2 production, whereas only DENV3 NS1 immunization resulted in strong crossreactive responses against DENV1 NS1 (Supplemental Fig. 3 ).
ML-RR-cGAMP-NS1 vaccination confers significant protection against DENV-induced pathogenesis
Given the ability of CDN compounds to induce substantial Ab and T cell responses, we tested whether immunization with NS1 in combination with ML-RR-cGAMP could prevent lethal DENV disease in Ifnar 2/2 mice. ML-RR-cGAMP is a potent activator of T cell immunity, capable of binding all common STING alleles (data not shown). Ifnar 2/2 mice were immunized two times with 20 mg of DENV1-4 NS1 and ML-RR-cGAMP over a 3-wk period (days 0 and 21) and challenged with DENV2 D220 4 wk after the last immunization (day 49) using ADE conditions. NS1-immunized mice showed fewer signs of DENV-induced morbidity and delayed disease progression compared with OVAimmunized animals and naive controls (Fig. 4A) . Vaccination with DENV1 NS1, DENV2 NS1, or DENV3 NS1 in combination with ML-RR-cGAMP resulted in significant protection compared with OVA-ML-RR-cGAMP-immunized controls or to naive mice. Indeed, survival among NS1-immunized animals was 60 and 70% for DENV1 NS1 and DENV2 NS1 or DENV3 NS1, respectively, compared with 11% in OVA-immunized mice and 20% among naive controls. Although only 30% of DENV4 NS1-ML-RR-cGAMP-immunized mice survived lethal DENV infection, mortality was significantly delayed (p , 0.05) compared with OVA-immunized animals. As a positive control, a low-dose (10 5 PFU) primary homologous infection with the parental DENV2 strain PL046 conferred 100% protection against lethal challenge (Fig. 4B) . Finally, in two independent experiments, immunizations with ML-RR-cGAMP in combination with DENV2 NS1 conferred similar or greater protection than MPLA-DENV2 NS1 vaccinations against lethal DENV2 D220 infection (Fig. 5) .
Anti-DENV2 NS1 Ab responses induced by ML-RR-cGAMP-NS1 vaccination are associated with protection against lethal dengue challenge Previously, we showed that passive transfer of NS1-immune serum and anti-NS1 mAb prevents NS1-induced lethality in vivo (5) . To determine if Ab responses in mice immunized with ML-RR-cGAMP-NS1 were associated with protection, serum samples were tested by ELISA against NS1 proteins from the four DENV serotypes. Notably, mice that were protected against lethal DENV challenge developed significantly higher anti-DENV2 NS1 IgG titers than those that succumbed to the infection. Ab titers against DENV1 NS1 and DENV3 NS1 showed a similar trend, albeit differences between protected and nonprotected groups were not statistically significant (Fig. 6) .
Sera from mice immunized with ML-RR-cGAMP-NS1 do not enhance DENV infection in vitro
ADE is the phenomenon by which weakly neutralizing and/or insufficient amounts of pre-existing anti-DENV Abs facilitate DENV infection of FcgR-bearing cells. This results in increased viral replication and can potentially lead to more severe disease. Because NS1 is not a structural component of the DENV virion, anti-NS1 Abs should not enable ADE. To examine whether sera from mice immunized with ML-RR-cGAMP-NS1 could enhance DENV infection in vitro, pooled serum samples were incubated with DENV2 D220 virus and used to infect K562 cells, a human erythroleukemic cell line that expresses FcgRIIA (CD32A) and is nonpermissive in the absence of enhancing Abs. Importantly, sera from mice vaccinated with DENV NS1 in combination with ML-RR-cGAMP did not allow infection of K562 cells. In contrast, sera from mice immunized with PL046 enabled DENV2 D220 infection, with peak enhancement between 1:135 and 1:405 serum dilutions (Supplemental Fig. 4) . 
Discussion
Earlier research had indicated that NS1 antigenemia in DENVinfected patients is associated with disease severity (43-45); however, it was not shown until recently that NS1 is directly involved in triggering endothelial permeability and vascular leak, and that immune responses against NS1 can prevent lethal DENV infection (5, 46) . On the basis of these findings, we sought to characterize immune responses and assess the protective efficacy of immunization with NS1 in combination with the CDN compound ML-RR-cGAMP or ML-RR-cGAMP-D, which are phosphodiesterase resistant, highly lipophilic activators of all common human STING alleles (31 in combination with CDNs induced overall more robust T cell responses than NS1-MPLA vaccination. Similar results were obtained when using OVA as an immunogen, which also allowed us to assess CD8 + T cell responses by circumventing the lack of cytotoxic T cell epitopes in DENV NS1 for the C57BL/6 (H-2K b ) background. As expected, immunization of NS1 adjuvanted with ML-RR-cGAMP and ML-RR-cGAMP-D resulted in higher frequencies of cytokine-producing CD4 + and CD8 + T cells than immunization with MPLA. Nonetheless, previous research indicates that MPLA is capable of inducing considerable T cell responses at higher immunization doses (52, 53) . There is a paucity of studies addressing the possible protective role of NS1-specific T cells against DENV infection. However, investigations in DENV-infected patients indicate that CD4 + T cells preferentially target NS1, the envelope, and capsid, the same proteins thought to be recognized by B cells (18) . In clinical trials, the NIH TV-003 DENV vaccine candidate induced NS1-specific CD4 + and CD8 + T cell responses comparable in breadth and magnitude to those found upon natural infection (54, 55) . Furthermore, a study testing an NS1-based DNA vaccine in mice indicated that both NS1-specific Abs and CD4 + T cells are critical for protection against DENV infection (17) . Thus, these data suggest that the (56) . In addition, IgG1, IgG2b, and IgG3 titers were comparable between mice immunized with NS1-ML-RR-cGAMP-D and NS1-MPLA, indicating that for these IgG subclasses, both adjuvants induce similar humoral immunity. In both WTB6 and Ifnar 2/2 mice, ML-RR-cGAMP-D induced stronger serotype-specific T cell responses than vaccination with MPLA. Nonetheless, only immunization with DENV3 NS1 and ML-RR-cGAMP-D elicited significantly higher crossreactive responses to DENV1 NS1 than MPLA, probably due to the ability of CDNs to induce more robust polyfunctional CD4 + T cell responses than MPLA (48) and because the NS1 sequence of both serotypes is closely related.
To assess the protective efficacy of NS1-ML-RR-cGAMP immunizations, Ifnar 2/2 mice were vaccinated twice with NS1 from each DENV serotype and challenged with lethal DENV2 D220
infection. Compared with OVA-ML-RR-cGAMP-immunized Ifnar 2/2 mice, immunizations with each of the four NS1 serotypes combined with ML-RR-cGAMP conferred significant protection against DENV2-induced morbidity and mortality. Importantly, mice immunized with ML-RR-cGAMP in combination with DENV2 NS1 showed comparable or greater protection than animals vaccinated with DENV2 NS1-MPLA/AddaVax, underscoring the substantial immunogenicity of CDN adjuvants. Using NS1-MPLA/AddaVax immunizations, we previously reported higher levels of homotypic and heterotypic protection than those observed in this study (5) ; however, in that study, mice were immunized three times by i.p. injection. Notwithstanding, the two-dose vaccination schedule and s.c. immunization route used in this study are more appealing from a vaccine-development perspective, and future research should aim to increase the immunogenicity and protective efficacy of this vaccination regimen. In general, immunocompetent rodent models are better suited for the assessment of vaccine-induced immunity and protective efficacy. However, the use of these models for the evaluation of dengue vaccine candidates is hindered by the inability of DENV to infect immunocompetent mice. DENV NS3 and NS5 proteins trigger degradation of human but not murine STING and STAT2, respectively, which are central components of the IFN signaling pathway (57) (58) (59) . This enables DENV to suppress the IFN response, replicate, and cause disease in humans but not wild-type mice. Thus, most DENV infection models use mice deficient in the IFN pathway, which display virus tropism similar to humans and a vascular leak syndrome with key features of severe dengue disease (60, 61) . Importantly, our data show that Ifnar 2/2 mice are capable of mounting robust Ab and T cell responses as a result of adjuvanted protein immunization. Additionally, a previous study demonstrated that cytotoxic responses to DENV infection-including CD8 + T cell proliferation, degranulation, and cytokine production-can develop in the absence of IFN-a/b signaling (62) .
Protection against DENV challenge among NS1-immunized mice is likely Ab-mediated, and previous studies have demonstrated that passive transfer of anti-NS1 Abs are capable of preventing DENV-induced mortality (5, 9, 10) . Furthermore, Ab responses against the wing domain of DENV NS1 have been associated with protection against DENV challenge in mice and reduced disease severity in humans (15, 16) . In this study, we show that the development of high anti-DENV2 NS1 titers is associated with protection from lethal DENV2 challenge, regardless of the NS1 serotype used for immunization. Thus, this provides further evidence that anti-NS1 titers correlate with protection from DENV-induced morbidity and mortality.
An important observation from this study is that Ifnar 2/2 mice are capable of mounting potent responses as a result of immunization with CDNs. Indeed, although these compounds activate the production of type I IFNs through the activation of the STING pathway, they have also been shown to work in Ifnar 2/2 mice, which are deficient in IFN-a/b receptor signaling (63) . In addition, previous research has also indicated that type I IFN signaling is nonessential for the induction of humoral responses by CDN-adjuvanted subunit vaccines (49, 64) . cGAMP can also be delivered through gap junctions to bystander cells, leading to STING activation and subsequent antiviral immunity independent of type I IFN signaling (65) . Thus, these data underscore the ability of CDN compounds to induce protective immunity through multiple signaling pathways, even in the absence of autocrine and paracrine type I IFN signaling. The necessity for using Ifnar
mice in this infection model may also obscure the actual potency of these CDNs relative to other NF-kB-dependent TLR agonists, such as MPLA. Therefore, MyD88/TRIF-dependent TLR agonists, such as MPLA, may be suboptimal for T cell priming against infectious disease Ags. The induction of potent T cell responses by soluble proteinin-adjuvant formulations has remained a difficult task. CDNs have shown promising results as vaccine adjuvants for intracellular pathogens in animal models, and their immunostimulatory properties can be readily optimized through chemical synthesis (27) . Importantly, phase I clinical trials for a synthetic human STINGactivating CDN (ADU-S100) as a chemotherapeutic agent alone and in combination with checkpoint inhibition are currently in progress (ClinicalTrials.gov NCT02675439 and NCT03172936). However, to date there are no human studies assessing CDNs as adjuvants against infectious agents.
In conclusion, we demonstrate that NS1-CDN immunizations induce potent Ab and T cell responses in both WTB6 and Ifnar 2/2 mice and confer significant protection from lethal DENV infection. We also show that anti-NS1 Ab titers in NS1-immunized mice are associated with protection, adding to previous research indicating that humoral responses against DENV NS1 are potential correlates of protection. Taken together, our results support the inclusion of NS1 in dengue vaccine candidates. 
